Donald E. Bobo Jr., who serves as CVP for Strategy and Corporate Development at Edwards Lifesciences Corp (NYSE: EW), executed a sale of 24,000 shares of the company’s common stock on February 25, 2026. The transaction generated $2,012,076 in proceeds, based on a weighted average sales price of $83.8365 per share. Individual trade prices in the block ranged from $83.66 to $83.96.
The sale took place while Edwards shares were trading near a 52-week high of $87.89, with the stock quoted at $85.90 at the time reported. Analysis by InvestingPro noted that the stock appears overvalued relative to its Fair Value. Edwards carries a market capitalization of $49.8 billion and a price-to-earnings ratio of 47.36.
Following the disposition, Mr. Bobo’s direct ownership in Edwards stands at 21,266.2532 shares. He retains additional positions indirectly, holding 38,900.5862 shares through a 401(k) account and 121,756 shares held by a trust.
For readers seeking additional proprietary commentary, InvestingPro is reported to offer nine extra exclusive tips and analysis covering Edwards Lifesciences.
Separately from insider activity, Edwards reported its fourth-quarter 2025 financial results, delivering an adjusted earnings per share of $0.58, which missed analysts’ expectations of $0.62. The company’s revenue for the quarter was $1.57 billion, topping the consensus estimate of $1.55 billion, and representing an 11.6% increase year over year.
Following the earnings release, Stifel reiterated a Buy rating on Edwards Lifesciences and set a price target of $110.00. The company also announced an expansion of its Every Heartbeat Matters initiative, a program intended to broaden access to structural heart treatment. The expansion aims to enable access for an additional 2 million patients by 2030; since 2014, the program has reportedly benefited over 4 million underserved patients globally.
These disclosures place the insider sale and the company’s recent operational developments in context: the stock is trading at elevated levels, the latest quarter showed revenue growth but an EPS shortfall versus expectations, and the firm continues to pursue an access-driven social initiative alongside analyst coverage maintaining a constructive price target.
Article note: This report presents transaction details, ownership figures, recent financial results, analyst commentary, and program expansion details as provided in company and market disclosures.